| Name | Title | Contact Details |
|---|
Natural Partners offers quality wholesale vitamins and supplements and a convenient way for health care practitioners to better serve their patients.
The Mason City Clinic was formed on January 1, 1989, with the merger of three physician groups -- Surgical Associates, Internal Medicine Associates and Independent Medical Surgical Group.
Provation is a leading provider of clinical productivity software for healthcare professionals, with solutions for intelligent procedure documentation (Provation® MD and Provation® Apex), order set and care plan management (Provation® Order Sets and Provation® Care Plans), and EHR-embedded clinical documentation templates (Provation® Clinic Note). Our software helps providers increase operational efficiencies, business profitability and regulatory compliance by improving quality, streamlining workflows and enabling the generation of insights. Trusted by leading physicians globally, we serve approximately 1,500 hospitals and 1,000 ambulatory surgery centers (ASCs), including 16 of the top 20 U.S. hospitals for gastroenterology (GI) and GI surgery. Provation is headquartered in Minneapolis, MN and is owned by Clearlake Capital Group, L.P.
Context 4 Healthcare is a Naperville, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.